Astellas Pharma (4503.T) Stock Price
Astellas Pharma Price
Over the last 19 years Astellas Pharma grew revenue by 4.5% annually, reaching 2.14 T JPY. Earnings per share have grown at 4.3% per year over the last 19 years. For Astellas Pharma, the net margin of 13.6% is up versus 9.6% a few years ago. At today's price the dividend yield works out to roughly 4.79%. The payout ratio is around 381% of earnings. The dividend has grown at 10.3% per year over the past 19 years. The consensus 12-month price target for Astellas Pharma is 2,091.00 JPY, about 12.8% below where the stock trades today. Of 20 analysts, 8 rate the stock a buy — an overall Hold consensus. The stock trades about 52% above its 52-week low.
Astellas Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Astellas Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Astellas Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Astellas Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Astellas Pharma Price |
|---|---|
| 9/25/2026 | 2,399.00 JPY |
| 9/24/2026 | 2,369.00 JPY |
| 9/21/2026 | 2,400.47 JPY |
| 9/18/2026 | 2,373.50 JPY |
| 9/17/2026 | 2,345.00 JPY |
| 9/16/2026 | 2,320.50 JPY |
| 9/15/2026 | 2,313.50 JPY |
| 9/14/2026 | 2,269.00 JPY |
| 9/11/2026 | 2,225.00 JPY |
| 9/10/2026 | 2,216.50 JPY |
| 9/9/2026 | 2,237.00 JPY |
| 9/8/2026 | 2,280.50 JPY |
| 9/7/2026 | 2,324.50 JPY |
| 9/4/2026 | 2,364.00 JPY |
| 9/3/2026 | 2,423.50 JPY |
| 9/2/2026 | 2,389.50 JPY |
| 9/1/2026 | 2,417.00 JPY |
| 8/31/2026 | 2,370.00 JPY |
| 8/28/2026 | 2,378.00 JPY |
| 8/27/2026 | 2,389.00 JPY |
| 8/26/2026 | 2,420.50 JPY |
| 8/25/2026 | 2,402.50 JPY |
| 8/24/2026 | 2,399.50 JPY |
| 8/21/2026 | 2,388.50 JPY |
| 8/20/2026 | 2,411.50 JPY |
| 8/19/2026 | 2,337.00 JPY |
| 8/18/2026 | 2,310.50 JPY |
| 8/17/2026 | 2,289.00 JPY |
| 8/14/2026 | 2,356.50 JPY |
| 8/13/2026 | 2,327.50 JPY |
Astellas Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Astellas Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUET JPY |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMET JPY |
| EBITB JPY |
| EBIT MARGIN% |
| NET INCOMEB JPY |
| NET INCOME GROWTH% |
| DIVIDENDDIV.JPY |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESB |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 | 1.31 | 1.30 | 1.31 | 1.30 | 1.25 | 1.30 | 1.52 | 1.60 | 1.91 | 2.14 | 2.33 | 2.17 | 1.94 | 1.85 | 1.86 |
| 10.06 | -4.45 | -0.86 | 0.46 | -0.42 | -3.94 | 3.73 | 17.16 | 5.60 | 19.25 | 11.87 | 8.99 | -6.81 | -10.87 | -4.47 | 0.58 |
| 75.55 | 75.57 | 77.37 | 77.64 | 78.73 | 80.31 | 80.48 | 81.01 | 81.76 | 81.74 | 74.55 | 74.55 | 74.55 | 74.55 | 74.55 | 74.55 |
| 1.04 | 0.99 | 1.01 | 1.01 | 1.02 | 1.00 | 1.04 | 1.23 | 1.31 | 1.56 | 1.59 | 1.74 | 1.62 | 1.44 | 1.38 | 1.39 |
| 268.70 | 276.42 | 271.12 | 280.14 | 279.42 | 250.90 | 220.02 | 285.43 | 124.61 | 263.54 | 419.70 | 451.75 | 424.14 | 320.88 | 337.10 | 318.02 |
| 19.57 | 21.07 | 20.85 | 21.44 | 21.48 | 20.08 | 16.97 | 18.80 | 7.77 | 13.78 | 19.62 | 19.38 | 19.52 | 16.57 | 18.22 | 17.09 |
| 193.69 | 218.70 | 164.68 | 222.27 | 195.41 | 120.59 | 124.09 | 98.71 | 17.05 | 50.75 | 291.54 | 358.38 | 361.85 | 283.09 | 258.30 | 243.07 |
| 42.57 | 12.91 | -24.70 | 34.97 | -12.08 | -38.29 | 2.90 | -20.45 | -82.73 | 197.72 | 474.49 | 22.93 | 0.97 | -21.77 | -8.76 | -5.90 |
| 33.00 | 35.00 | 37.00 | 39.00 | 41.00 | 46.00 | 55.00 | 65.00 | 72.00 | 76.00 | 115.00 | 138.00 | 165.60 | 198.72 | – | – |
| 3.13 | 6.06 | 5.71 | 5.41 | 5.13 | 12.20 | 19.57 | 18.18 | 10.77 | 5.56 | 51.32 | 20.00 | 20.00 | 20.00 | – | – |
| 2.11 | 2.02 | 1.92 | 1.88 | 1.86 | 1.85 | 1.82 | 1.80 | 1.79 | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Astellas Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Astellas Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Astellas Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Astellas Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Astellas Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Astellas Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Astellas Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Astellas Pharma business model & stock analysis
Astellas Pharma SWOT Analysis
Strengths
Astellas Pharma Inc has built a strong brand reputation in the pharmaceutical industry through its high-quality products, ethical business practices, and commitment to innovation.
The company offers a diverse range of pharmaceutical products across multiple therapeutic areas, providing a competitive advantage and reducing dependence on a single product or market.
Astellas Pharma Inc has a global presence with operations in multiple countries, allowing the company to capitalize on international market opportunities and reach a larger customer base.
The company invests significantly in research and development, fostering innovation and enabling the development of novel drugs and treatments that address unmet medical needs.
Weaknesses
Astellas Pharma Inc relies heavily on a few key products for a significant portion of its revenue, making the company vulnerable to potential declines in sales if these products face competition or patent expiration.
The pharmaceutical industry is subject to strict regulations and compliance requirements, and changes in regulations or unexpected challenges in obtaining regulatory approvals can impact the company's product pipeline and business operations.
Opportunities
Astellas Pharma Inc can expand its market presence by targeting emerging markets, where growing populations, increasing healthcare spending, and rising awareness of healthcare contribute to significant growth opportunities.
The company can explore opportunities in the field of biotechnology, which offers potential for the development of innovative therapies and treatments that align with changing medical needs and technological advancements.
Threats
Astellas Pharma Inc operates in a highly competitive industry, facing competition from other pharmaceutical companies, generic drug manufacturers, and new entrants, which can impact market share and pricing.
The company's intellectual property rights may be challenged or infringed upon by competitors, affecting market exclusivity and potentially leading to revenue loss.
Government interventions such as price controls and healthcare reforms can impact the pricing and reimbursement of pharmaceutical products, posing financial challenges and potentially affecting profitability for Astellas Pharma Inc.
Astellas Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Astellas Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Astellas Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Astellas Pharma's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Astellas Pharma's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Astellas Pharma's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Astellas Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Astellas Pharma stock splits
Since 1991, a total of 5.5 shares have been converted from one Astellas Pharma share.
Astellas Pharma Dividend History
37 years of dividend payments · 12 consecutive increases
Astellas Pharma dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Astellas Pharma dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Astellas Pharma forecasts and price targets in September 2026
Analyst Price Targets 2026Astellas Pharma Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/4/2026 | 62.10JPY | - | 582.35 BJPY | - | 2026 Q3 |
| 8/5/2026 | 52.62JPY | 79.15JPY | 559.53 BJPY | - | 2026 Q2 |
| 4/27/2026 | 30.12JPY | 23.93JPY | 512.17 BJPY | - | 2026 Q1 |
| 2/4/2026 | 45.93JPY | 56.04JPY | 529.88 BJPY | - | 2025 Q4 |
| 10/30/2025 | 29.81JPY | 44.22JPY | 481.09 BJPY | - | 2025 Q3 |
| 7/30/2025 | 19.87JPY | 38.22JPY | 454.50 BJPY | - | 2025 Q2 |
| 4/25/2025 | 21.32JPY | 41.84JPY | 442.47 BJPY | - | 2025 Q1 |
| 2/4/2025 | 18.94JPY | -54.55JPY | 447.53 BJPY | - | 2024 Q4 |
| 10/30/2024 | 15.97JPY | 20.06JPY | 427.37 BJPY | - | 2024 Q3 |
| 8/1/2024 | 12.33JPY | 21.00JPY | 412.11 BJPY | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Astellas Pharma stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Astellas Pharma shareholder structure
| % | Name |
|---|---|
6.40186% | |
3.27914% | |
2.72735% | |
2.35050% | |
2.25371% | |
1.64560% |
Astellas Pharma Beneficial Ownership Filings (SEC 13D/G)
Astellas Pharma Executives and Management Board
23 members · avg. age 61 · 26 % women
Mr. Naoki Okamura (61)
President, Chief Executive Officer, Representative Director · since 2016
461.00 M JPY
Management
Mr. Katsuyoshi Sugita (56)
Vice President, Chief People Officer, Chief Ethics & Compliance Officer, Manager of Human Resource Division, Representative Director · since 2022
Mr. Atsushi Kitamura
Chief Financial Officer, Senior Managing Executive Officer
Dr. Yoshitsugu Shitaka
Senior Managing Executive Officer, Chief Scientific Officer
Ms. Catherine Levitt
General Counsel
Mr. Hideki Shima
Senior Managing Executive Officer, Chief Manufacturing Officer
Dr. Tadaaki Taniguchi
Senior Managing Executive Officer, Chief Medical Officer
Board of Directors
Mr. Kenji Yasukawa (63)
Chairman of the Board, Chairman of the Board of Directors, Representative Director
Ms. Rika Hirota (57)
Director
Ms. Rie Akiyama (54)
Independent Director
Ms. Tomoko Aramaki (55)
Independent Director
Mr. Masahiro Miyazaki (70)
Independent Director
Ms. Mika Nakayama (63)
Independent Director
Astellas Pharma Supply Chain
Astellas Pharma Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.19 | 0.31 | 0.69 | ||
| 2 | -0.34 | -0.03 | 0.68 | ||
| 3 | 0.66 | 0.39 | 0.66 | ||
| 4 | 0.75 | 0.50 | 0.62 | ||
| 5 | 0.62 | 0.52 | 0.61 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.61 | -0.24 | — | ||
| 2 | -0.49 | -0.12 | — | ||
| 3 | -0.66 | -0.48 | — | ||
| 4 | -0.51 | -0.20 | — | ||
| 5 | -0.68 | -0.44 | -0.73 |
Frequently asked questions about Astellas Pharma
The business model of Astellas Pharma Inc, a leading pharmaceutical company, focuses on research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas Pharma Inc specializes in therapeutic areas such as urology, immunology, nephrology, and oncology. With a patient-centric approach, Astellas strives to improve the health and well-being of people worldwide by delivering breakthrough treatments. They collaborate with healthcare professionals, organizations, and researchers to drive scientific advancements and enhance patient outcomes. Astellas Pharma Inc's dedication to innovation, strategic partnerships, and global expansion sets it apart in the pharmaceutical industry, allowing them to continue making a positive impact on the lives of patients.
Astellas Pharma Inc is primarily active in the pharmaceutical industry. The company specializes in the research, development, manufacturing, and sale of innovative pharmaceutical products. With a focus on therapeutic areas such as oncology, urology, immunology, and infectious diseases, Astellas Pharma Inc aims to improve patients' lives through the discovery of innovative and effective treatments. As a renowned global pharmaceutical company, Astellas Pharma Inc actively collaborates with healthcare professionals, organizations, and academic institutions to advance medical knowledge and provide quality healthcare solutions worldwide.
The main competitors of Astellas Pharma Inc in the market include Pfizer, Johnson & Johnson, Novartis, GlaxoSmithKline, and Merck & Co.
Astellas Pharma Inc. is a leading pharmaceutical company founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Based in Tokyo, Japan, Astellas specializes in the research, development, and commercialization of innovative drugs and medical solutions. With a strong focus on areas such as urology, immunology, and oncology, Astellas has established itself as a global player in the healthcare industry. The company continually strives to improve patient lives through its cutting-edge products and dedication to scientific advancements. Astellas Pharma Inc. remains committed to addressing unmet medical needs and contributing to the overall well-being of communities worldwide.
Astellas Pharma Inc, a renowned pharmaceutical company, has achieved several significant milestones throughout its history. One notable accomplishment is the discovery and development of innovative drugs that have improved the treatment options for various medical conditions. The company has also excelled in creating strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies to foster research collaboration and enhance its product pipeline. Additionally, Astellas Pharma Inc has successfully expanded its global presence by entering new markets and establishing strong footholds in key regions worldwide. These accomplishments demonstrate Astellas Pharma Inc's commitment to advancing healthcare through groundbreaking research, development, and strategic growth initiatives.
Astellas Pharma Inc is primarily present in various countries and regions worldwide. The company has an extensive global presence, with operations spanning across North America, Europe, Asia, and numerous other regions. Astellas Pharma Inc is actively engaged in pharmaceutical research, development, and commercialization in countries such as the United States, Japan, Europe (including the United Kingdom and Germany), China, and many more. With its commitment to improving the health and well-being of people globally, Astellas Pharma Inc has established a significant presence in key markets around the world.
Astellas Pharma Inc represents values of integrity, dedication, and innovation. With a strong corporate philosophy centered around "Contributing toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," Astellas Pharma Inc emphasizes the importance of patient well-being and healthcare advancement. Through their research and development efforts, they strive to introduce cutting-edge therapies and medicines to meet unmet medical needs. With an unwavering commitment to ethical conduct and a focus on creating sustainable value, Astellas Pharma Inc demonstrates its dedication to improving global health outcomes.
Analysts currently set an average price target of 2,145.92 JPY for the Astellas Pharma stock (median: 2,091.00 JPY), implying -9.4 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Astellas Pharma stock: 7 recommend buying, 12 holding and 1 selling.
Converted at the current exchange rate, the Astellas Pharma share trades at 13.28 EUR (2,399.00 JPY).
The Astellas Pharma share (4503.T) is listed on 5 stock exchanges, including: Tokio (JPX) (4503.T), Frankfurt (YPH.F), München (YPH.MU), Düsseldorf (YPH.DU).
Astellas Pharma Inc. is a Japanese pharmaceutical company specializing in the development and marketing of innovative therapies for various diseases. The company is divided into three main areas: Pharmaceuticals, OTC products (Non-Prescription products), and Diagnostics.
The revenue of Astellas Pharma is 2.14 T JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Astellas Pharma is 291.54 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Astellas Pharma is currently 14.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Astellas Pharma stock.
The price-to-sales ratio (P/S) of Astellas Pharma is currently 2.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Astellas Pharma stock.
The Eulerpool Quality Score for Astellas Pharma is 4/10.
The ISIN of Astellas Pharma is JP3942400007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Astellas Pharma is 856273. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Astellas Pharma is 4503.T. The ticker symbol is used to trade Astellas Pharma shares on the stock exchange.
Over the past 12 months, Astellas Pharma paid a dividend of 115.00 JPY . This corresponds to a dividend yield of about 4.79 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 138.00 JPY.
The current dividend yield of Astellas Pharma is 4.79 %.
Astellas Pharma pays a dividend, distributed in the months of September, March.
Astellas Pharma paid dividends every year for the past 36 years.
For the upcoming 12 months, dividends amounting to 138.00 JPY are expected. This corresponds to a dividend yield of 5.75 %.
Astellas Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Astellas Pharma from 6/1/2026 amounting to 39 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2026.
The last dividend was paid out on 6/1/2026.
In the year 2025, Astellas Pharma distributed 76 JPY as dividends.
The dividends of Astellas Pharma are distributed in JPY.
Astellas Pharma stock
Astellas Pharma Peer Group
Astellas Pharma Ticker
Astellas Pharma FIGI
All fundamentals and in-depth analysis of Astellas Pharma
Our stock analysis for Astellas Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.